Hopes Inch Higher For Annexon’s AMD Candidate After New Phase II Analyses
Regulatory Talks Ahead
Executive Summary
The US biotech’s ANX007 has some analysts cautiously optimistic as post hoc Phase II analyses backed its ability to improve visual acuity in geographic atrophy secondary to age-related macular edema despite a prior primary endpoint miss.